Cytokinetics

About

Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.

South San Francisco,California,United States
251 - 500
http://cytokinetics.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $450M
Industries: Biopharma,Biotechnology,Health Care
Founded date: Jan 1, 1998
Number Of Employee: 251 - 500
Operating Status: Active
Stock Symbol: nasdaq:CYTK
Legal Name: Cytokinetics, Inc.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

9

$1.23B

Cytokinetics has raised a total of $1.23B in funding over 2 rounds. Their latest funding was raised on Jul 1, 2022 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jul 1, 2022	Post-IPO Debt	$450M	1	Royalty Pharma	—	Detail
Jul 21, 2021	Post-IPO Equity	$316.25M	—	—	—	Detail
Jul 16, 2020	Post-IPO Equity	$201.30M	—	—	—	Detail
Feb 20, 2014	Post-IPO Equity	$37.40M	—	—	—	Detail
Jun 19, 2012	Post-IPO Equity	$42.50M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Cytokinetics has made 1 investments. Their most recent investment was on Nov 16, 2017, when zolar raised €4M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Nov 16, 2017 zolar	Series A	€4M	Clean Energy	—

Investors

Number of Lead Investors

Number of Investors

3

5

Cytokinetics is funded by 5 investors. Royalty Pharma and Deepfield are the most recent investors.

Investor Name	Lead Investor	Funding Round
Royalty Pharma	Yes	Post-IPO Debt
Deepfield	Yes	Post-IPO Equity
Vulcan	Yes	Series E
Federated Kaufmann Fund	—	Post-IPO Equity
Red Abbey Venture Partners	—	Post-IPO Equity